April 5, 2019

Catabasis Shares March 2019 Newsletters

Catabasis shared the latest edition of their community newsletter (also available in Spanish), including an update on their currently recruiting Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Download the Catabasis newsletters: English Spanish

Learn More

April 4, 2019

End Duchenne Tour Recap: Omaha, NE

PPMD had the opportunity to travel to Omaha, NE on March 30 for our second End Duchenne Tour stop of 2019. We were joined by over 50 people including 18 families, 9 industry partners, and 10…

Learn More

February 19, 2019

End Duchenne Tour Recap: Las Vegas, NV

PPMD was thrilled to head to Las Vegas, NV for our first End Duchenne Tour stop of 2019 on February 2. More than 45 people came together to learn about the latest information and resources for Duchenne…

Learn More

February 19, 2019

Catabasis Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne

Catabasis Pharmaceuticals, Inc. shared additional clinical results from the MoveDMD trial of edasalonexent at the XVII International Conference on Duchenne and Becker Muscular Dystrophy in Rome, Italy this weekend. We are pleased to learn that in…

Learn More

January 8, 2019

Meeting Update: Inflammation in Duchenne

Last month, PPMD convened a day and half meeting – Inflammation in Duchenne: Current and New Treatment Strategies – to bring academic and clinical researchers together to discuss advancements that could be made by treating…

Learn More

January 3, 2019

Catabasis Phase 3 PolarisDMD Trial for Edasalonexent Update & Additional Trial Sites Open for Enrollment

Catabasis Pharmaceuticals shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne. PolarisDMD clinical trial…

Learn More

December 17, 2018

End Duchenne Tour Recap: Cincinnati, OH

PPMD headed to Cincinnati, OH for our End Duchenne Tour stop on November 17, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families. PPMD…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More

November 15, 2018

WATCH: PolarisDMD – Phase 3 Clinical Trial of Edasalonexent – Webinar Recording

PPMD and Catabasis as hosted a webinar on Wednesday, November 7 to discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy, which is enrolling boys ages 4 to 7 (up to…

Learn More

September 25, 2018

Catabasis Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne

Catabasis Pharmaceuticals, Inc. announced the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy. PolarisDMD clinical trial sites across the United States will open in the coming days for enrollment of the…

Learn More